In early April, the Committee for Medicinal Products for Human Use (CHMP) gave GSK recommended approval for its gene therapy treatment for the “bubble boy” orphan disease. Since the welcomed decision, the UK pharma giant and its Italian research partners are now planning on opening up new research centres with a focus on gene therapies and other treatments.
07
Apr